Edivoxetine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413999

CAS#: 1194374-05-4 (HCl)

Description: Edivoxetine HCl is a norepinephrine reuptake inhibitor used in the treatment of Depression and Attention Deficit Disorder

Chemical Structure

Edivoxetine HCl
CAS# 1194374-05-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 413999
Name: Edivoxetine HCl
CAS#: 1194374-05-4 (HCl)
Chemical Formula: C18H27ClFNO4
Exact Mass: 375.1613
Molecular Weight: 375.87
Elemental Analysis: C, 57.52; H, 7.24; Cl, 9.43; F, 5.05; N, 3.73; O, 17.03

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1194374-05-4 (HCl)   1194508-25-2 (free base)  

Synonym: Edivoxetine HCl; Edivoxetine hydrochloride; LY 2216684 HCl; LY-2216684 HCl; LY2216684 HCl

IUPAC/Chemical Name: (R)-2-(5-fluoro-2-methoxyphenyl)-1-((S)-morpholin-2-yl)-1-(tetrahydro-2H-pyran-4-yl)ethan-1-ol hydrochloride


InChi Code: InChI=1S/C18H26FNO4.ClH/c1-22-16-3-2-15(19)10-13(16)11-18(21,14-4-7-23-8-5-14)17-12-20-6-9-24-17;/h2-3,10,14,17,20-21H,4-9,11-12H2,1H3;1H/t17-,18+;/m0./s1

SMILES Code: COc1c(C[C@@](C2CCOCC2)([C@@H]3CNCCO3)O)cc(F)cc1.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 375.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Hoaglund Hyzer CS, Fadda HM, Rodriguez JO, Aburub A. Leveraging BCS in Development: A Case Study. Mol Pharm. 2015 Oct 5;12(10):3685-90. doi: 10.1021/acs.molpharmaceut.5b00450. Epub 2015 Sep 17. PubMed PMID: 26365521.

2: Le CC, MacMillan DW. Fragment Couplings via CO2 Extrusion-Recombination: Expansion of a Classic Bond-Forming Strategy via Metallaphotoredox. J Am Chem Soc. 2015 Sep 23;137(37):11938-41. doi: 10.1021/jacs.5b08304. Epub 2015 Sep 15. PubMed PMID: 26333771; PubMed Central PMCID: PMC4632494.

3: Kielbasa W, Lobo E. Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. J Clin Pharmacol. 2015 Dec;55(12):1422-31. doi: 10.1002/jcph.551. Epub 2015 Jul 29. PubMed PMID: 26011686.

4: Martinez JM, Ferguson MB, Pangallo BA, Oakes TM, Sparks J, Dellva MA, Zhang Q, Liu P, Bangs M, Ahl J, Goldberger C. Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder. Drugs Context. 2015 May 13;4:212279. doi: 10.7573/dic.212279. eCollection 2015. PubMed PMID: 26005493; PubMed Central PMCID: PMC4434861.

5: Oakes TM, Dellva MA, Waterman K, Greenbaum M, Poppe C, Goldberger C, Ahl J, Perahia DG. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder. Curr Med Res Opin. 2015 Jun;31(6):1179-89. doi: 10.1185/03007995.2015.1037732. Epub 2015 May 6. PubMed PMID: 25894953.

6: Ball SG, Atkinson S, Sparks J, Bangs M, Goldberger C, Dubé S. Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment. J Clin Psychopharmacol. 2015 Jun;35(3):266-72. doi: 10.1097/JCP.0000000000000302. PubMed PMID: 25815754.

7: Kielbasa W, Pan A, Pereira A. A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition. Eur Neuropsychopharmacol. 2015 Mar;25(3):377-85. doi: 10.1016/j.euroneuro.2014.12.009. Epub 2015 Jan 5. PubMed PMID: 25637266.

8: Wang SM, Han C, Pae CU. Criticisms of drugs in early development for the treatment of depression: what can be improved? Expert Opin Investig Drugs. 2015 Apr;24(4):445-53. doi: 10.1517/13543784.2014.985784. Epub 2014 Dec 20. PubMed PMID: 25529224.

9: Markowitz JS, Brinda BJ. A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. Expert Opin Drug Metab Toxicol. 2014 Sep;10(9):1289-99. doi: 10.1517/17425255.2014.939955. Epub 2014 Jul 14. Review. PubMed PMID: 25019201.

10: Ball S, Dellva MA, D'Souza DN, Marangell LB, Russell JM, Goldberger C. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Affect Disord. 2014;167:215-23. doi: 10.1016/j.jad.2014.06.006. Epub 2014 Jun 14. PubMed PMID: 24995890.

11: Lin DY, Kratochvil CJ, Xu W, Jin L, D'Souza DN, Kielbasa W, Allen AJ. A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014 May;24(4):190-200. doi: 10.1089/cap.2013.0043. PubMed PMID: 24840045; PubMed Central PMCID: PMC4026219.

12: Gibbs AA, Bautista CE, Mowlem FD, Naudts KH, Duka DT. Catechol-O-methyltransferase val158met genotype determines effect of reboxetine on emotional memory in healthy male volunteers. J Psychiatry Neurosci. 2014 May;39(3):E24-31. PubMed PMID: 24467942; PubMed Central PMCID: PMC3997609.

13: Kielbasa W, Tesfaye E, Luffer-Atlas D, Mitchell MI, Turik MA. The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor. Eur J Clin Pharmacol. 2013 Dec;69(12):2011-9. doi: 10.1007/s00228-013-1572-y. Epub 2013 Aug 17. PubMed PMID: 23955175; PubMed Central PMCID: PMC3832778.

14: Slattery CN, Deasy RE, Maguire AR, Kopach ME, Singh UK, Argentine MD, Trankle WG, Scherer RB, Moynihan H. Telescoped approach to aryl hydroxymethylation in the synthesis of a key pharmaceutical intermediate. J Org Chem. 2013 Jun 21;78(12):5955-63. doi: 10.1021/jo400647t. Epub 2013 Jun 6. PubMed PMID: 23718859.

15: Jin L, Xu W, Krefetz D, Gruener D, Kielbasa W, Tauscher-Wisniewski S, Allen AJ. Clinical outcomes from an open-label study of edivoxetine use in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013 Apr;23(3):200-7. doi: 10.1089/cap.2012.0016. PubMed PMID: 23607409.

16: Kielbasa W, Quinlan T, Jin L, Xu W, Lachno DR, Dean RA, Allen AJ. Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012 Aug;22(4):269-76. doi: 10.1089/cap.2011.0151. Epub 2012 Jul 31. PubMed PMID: 22849510.

17: Pangallo B, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res. 2011 Jun;45(6):748-55. doi: 10.1016/j.jpsychires.2011.03.014. Epub 2011 Apr 21. PubMed PMID: 21511276.